Groowe Groowe BETA

US Stock Market News

Stay on top of the US stock market with real-time breaking news and market-moving stories. Our platform continuously aggregates updates from trusted financial news sources, giving traders and investors a fast overview of events that may impact stock prices.

Whether you're tracking specific companies or scanning the broader market, the news feed helps you quickly identify important developments as they happen.

Create an account to access the live news feed. Access is free while the platform is in beta. Visitors without an account can still browse the latest headlines with a 15-minute delay.

⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Class Action Filed Against Duolingo, Inc. (DUOL) Over Securities Violations - Contact Levi & Korsinsky Today

accessnewswire.com
DUOL

Class Action Lawsuit Filed Against Baidu, Inc. (BIDU) - Recover Losses - Contact Levi & Korsinsky Before November 13, 2026

accessnewswire.com
BIDU

Securities Class Action Lawsuit Filed Against Better Home & Finance Holding Company (BETR) - Levi & Korsinsky Represents Shareholders

accessnewswire.com
BETR

Shareholders of Triller Group Inc. (ILLR): Protect Your Rights Before December 14, 2026 - Contact Levi & Korsinsky

accessnewswire.com
ILLR

December 14, 2026 Deadline: Join Class Action Lawsuit Against Gildan Activewear Inc. (GIL) - Contact Levi & Korsinsky

accessnewswire.com
GIL

Caledonia Mining Corporation Plc: Caledonia Group Signs US$150 Million Interim Financing Facilities Agreement to Support Construction of the Bilboes Gold Project

accessnewswire.com
CMCL

Securities Lawsuit Alert: Coastal Financial Corporation (CCB) Investors - Contact Levi & Korsinsky Before December 1, 2026

accessnewswire.com
CCB

QFIN ALERT: Securities Fraud Class Action Launched Against Qfin Holdings, Inc. - November 27, 2026 Deadline

accessnewswire.com
QFIN

Equiniti and Leading Banking and Investment Figures Convene to Answer: Can Share Plans Create Lifelong Investors?

globenewswire.com
NWG

T-Therapeutics announces oversubscribed $133 million Series B financing to achieve clinical proof-of-concept for first-in-class TCR bispecific therapies in cancer and autoimmune disease

globenewswire.com
LLY
View all news →